ADC Therapeutics SA
Symbol: ADCT (NYSE)
Company Description:
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
- Today's Open: $3.57
- Today's High: $3.96
- Today's Low: $3.502
- Today's Volume: 830.03K
- Yesterday Close: $3.67
- Yesterday High: $3.88
- Yesterday Low: $3.29
- Yesterday Volume: 739.40K
- Last Min Volume: 77
- Last Min High: $3.61
- Last Min Low: $3.61
- Last Min VWAP: $3.61
- Name: ADC Therapeutics SA
- Website: https://www.adctherapeutics.com
- Listed Date: 2020-05-15
- Location: EPALINGES, V8
- Market Status: Active
- CIK Number: 0001771910
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $354.25M
- Round Lot: 100
- Outstanding Shares: 99.23M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-06-13 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 3 | View |
| 2025-06-05 | 3/A | View |
| 2025-06-05 | 8-K | View |
| 2025-05-19 | SCHEDULE 13G/A | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-05-08 | 4 | View |
| 2025-04-24 | SCHEDULE 13G/A | View |
| 2025-04-21 | DEF 14A | View |